As of 30 Sep 2025, 1 institutional investors reported holding 60,616 shares of PROTAGONIST THERAPEUTICS INC - COM.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 60,616 | $4,026,721 | -$46,368 | $66.43 | 1 |
| 2025 Q2 | 61,314 | $3,388,825 | -$7,793 | $55.27 | 1 |
| 2025 Q1 | 61,455 | $2,971,964 | -$3,434 | $48.36 | 1 |
| 2024 Q4 | 61,526 | $2,374,904 | -$14,243 | $38.60 | 1 |
| 2024 Q3 | 61,895 | $2,785,275 | -$24,480 | $45.00 | 1 |
| 2024 Q2 | 62,439 | $2,163,511 | -$13,167 | $34.65 | 1 |
| 2024 Q1 | 62,819 | $1,817,354 | -$3,529 | $28.93 | 1 |
| 2023 Q4 | 62,941 | $1,443,237 | -$3,394 | $22.93 | 1 |
| 2023 Q3 | 63,089 | $1,052,325 | -$534 | $16.68 | 1 |
| 2023 Q2 | 63,121 | $1,743,402 | $0 | $27.62 | 1 |
| 2023 Q1 | 63,121 | $1,451,783 | $0 | $23.00 | 1 |
| 2022 Q4 | 63,121 | $688,650 | -$739,262 | $10.91 | 1 |
| 2022 Q3 | 130,881 | $1,103,000 | $0 | $8.43 | 1 |
| 2022 Q2 | 159,592 | $1,324,000 | $0 | $8.30 | 1 |